Monthly intravitreal injections with the VEGF antagonist ranibizumab reduces self-reported difficulty driving in patients with age-related macular degeneration. Medscape Medical News
Synexus Sets Its Sights on Ophthalmology
Synexus is set to take part in a number of global ophthalmology trials following recent investment in clinical research expertise and technology in this area. Chief Executive, Dr Christophe Berthoux says that ophthalmology offers considerable growth …
Novartis’ Vasella elected chairman at Alcon
Novartis’ chairman Daniel Vasella was elected board chairman of Alcon, increasing the Swiss drugmaker’s grip of the U.S. eyecare company as it tries to buy the stake it does not already own. Alcon’s Independent Director’s Committee (IDC), which has r…
AAO: Can Boomers Throw Away Their Reading Glasses? (CME/CE)
CHICAGO (MedPage Today) — With the baby-boom generation now firmly in the age range when near-range vision goes blurry, advances in refractive surgery and implants could allow many of them to do away with reading glasses, researchers said here.
Report on global ophthalmology drug and devices market
Global ophthalmology drug and devices market is witnessing a significant growth due to the increasing incidence and prevalence of eye related disorders such as presbyopia, macular degeneration, and diabetic retinopathy among the aging population. With …
UCI scientists receive CIRM grants to improve stem cell treatments
UC Irvine scientists will receive grants totaling $9.35 million to help create stem cell treatments for retinitis pigmentosa, Huntington’s disease and traumatic brain injury.